#United States #Princeton #Kenox Pharmaceuticals #Nasal Drug Products #Clinical Manufacturing

Kenox Pharmaceuticals Achieves Clinical Manufacturing Readiness

Kenox Pharmaceuticals Inc., a rapidly evolving contract development and manufacturing organization (CDMO), recently announced its full clinical manufacturing readiness for both nasal and inhaled drug products. This significant milestone marks an important step forward in the company’s mission to support pharmaceutical innovators in bringing their therapeutics to market more efficiently.

Located in Princeton, New Jersey, Kenox has made substantial strides in expanding its good manufacturing practices (GMP) analytical testing capabilities. This includes the introduction of in vitro bioequivalence (IVBE) testing, which is essential for companies focusing on nasal and inhaled therapies. According to Sitaram Velaga, the founder and CEO of Kenox, the goal has always been to expedite the clinical journey for their partners. By integrating development processes, GMP testing, and clinical manufacturing into one seamless operation, Kenox aims to minimize risks associated with early-stage programs.

The newly established clinical manufacturing readiness allows Kenox to facilitate small-scale fill-finish operations for a range of therapeutic candidates. These can include small molecules, peptides, and biologics, with batch sizes ranging from hundreds to a few thousand units, ideally suited for Phase I and Phase II clinical trials. This flexibility empowers biotech companies to navigate their early clinical phases with greater agility and certainty.

Kenox's repertoire of products extends from nebulizers and soft mist inhalers (SMIs) to nasal sprays and dry powder inhalers (DPIs). Coupled with proficient analytical and formulation development expertise, the organization's comprehensive OINDP performance testing and supporting IVBE studies significantly de-risk the development process. Kenox positions itself as a true one-stop solution, successfully supporting clients from initial feasibility studies to clinical supply and bioequivalence support.

The broad therapeutic areas that Kenox can now tackle stretch across various medical conditions. They encompass central nervous system (CNS) conditions like psychiatry, Alzheimer's disease, ALS, and Parkinson's disease, as well as pulmonary disorders such as asthma, COPD, pulmonary arterial hypertension (PAH), and idiopathic pulmonary fibrosis (IPF). Moreover, their services extend to pain management therapies and therapies aimed at select rare diseases.

Kenox Pharmaceuticals is inviting potential partnership discussions to expedite time to clinic and optimize time to market. With this expanded manufacturing capability, Kenox not only boosts its existing profiles but also enhances its market competitiveness, underscoring its commitment to delivering high-quality, innovative products.

As a specialized CDMO, Kenox's expertise lies in developing pharmaceutical aerosol and nasal drug products. This includes providing end-to-end solutions, from formulation design and analytical testing to IVBE testing and regulatory support. Their unique position allows them to help biopharmaceutical innovators streamline their clinical processes effectively.

In summation, Kenox Pharmaceuticals Inc. stands at the forefront of the nasal and inhaled drug development landscape. With its new clinical manufacturing readiness, the company is poised to play a crucial role in the development of groundbreaking therapies that can significantly improve patient outcomes worldwide.